Suppressive Activity of Mefloquine in Sporozoite-Induced Human Malaria
- 1 March 1976
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 9 (3) , 384-386
- https://doi.org/10.1128/aac.9.3.384
Abstract
Mefloquine hydrochloride [WR 142,490; α-(2-piperidyl)-2,8-bis(trifluoromethyl)-4-quinolinemethanol hydrochloride] was tested for suppressive effect on sporozoite-induced malaria in nonimmune volunteers living in an area where malaria is not naturally transmitted. Single doses of 250 mg were given at weekly intervals, 500 mg at intervals of 2 weeks and 1,000 mg at intervals of 4 weeks, to men bitten by 10 to 15 mosquitoes heavily infected with a chloroquine- and pyrimethamine-resistant strain of Plasmodium falciparum . None of the individuals so treated developed infections during the period of drug delivery or during the follow-up period of 60 days. Doses of 250 or 500 mg produced no adverse reactions; mild epigastric discomfort occurred in all three men given 1,000 mg. Sporozoite-induced P. vivax infections were suppressed by single doses of 250 mg of mefloquine given at weekly intervals, but malaria developed after completion of the course. At treatment intervals longer than 1 week, vivax malaria was not suppressed.Keywords
This publication has 4 references indexed in Scilit:
- Mefloquine (WR 142,490) in the Treatment of Human MalariaScience, 1975
- Clinical testing of new antimalarial compounds.1974
- Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey—model systems for basic biological and chemotherapeutic studiesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1973
- Treatment of Falciparum Malaria Caused by Strain Resistant to QuinineJAMA, 1970